Clover Biopharmaceuticals, Inc.
B-A10 Room No.1, Mansion
Chengdu Hi-tech Zone Hi-tech Incubation Park
Tianhe Incubator, Nan Yan Xian Tian Fu Avenue
Chengdu
610041
China
Tel: 028-85336966
Fax: 028-85336933
Website: http://www.cloverbiopharma.com/
Email: jiang.pu@cloverbiopharma.com
About Clover Biopharmaceuticals, Inc.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
LEADERSHIP:
Founders: Peng Liang, Xiaodong Wang and Jianwei Zhu
CSO: Joshua Liang
COO: Zheng Ping
CIO: Pu Jiang
CLINICAL TRIAL:
69 articles with Clover Biopharmaceuticals, Inc.
-
Clover to Participate in Morgan Stanley Virtual China Summit 2022
5/17/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced its participation in Morgan Stanley’s Virtual China Summit, May 24-26, 2022.
-
Clover’s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern
5/5/2022
Clover Biopharmaceuticals, Ltd. announced new promising data from a preclinical study on Clover’s bivalent vaccine candidate, which combines the trimeric spike antigens from the original SARS-CoV-2 strain and the Omicron variant.
-
Clover Appoints LiongHo Chua as President of Greater China
4/27/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointment of Mr. LiongHo Chua as President of Greater China.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Clover’s Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease
4/20/2022
Clover Biopharmaceuticals, Ltd. today announced additional data from SPECTRA, a global pivotal Phase 2/3 clinical trial, that shows SCB-2019 (CpG 1018/Alum) provides significant incremental protection against COVID-19.
-
Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022
4/19/2022
Clover Biopharmaceuticals, Ltd. today announced additional positive data from two ongoing studies evaluating SCB-2019 (CpG 1018/Alum).
-
Clover To Present at World Vaccine Congress Washington 2022
4/12/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that Igor Smolenov, Senior Vice President, Global Clinical Development, will deliver a presentation at the World Vaccine Congress Washington 2022.
-
Clover Reports Full Year 2021 Financial Results
3/29/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, reported financial results for the year ended December 31, 2021.
-
Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster
3/17/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive clinical results from several studies evaluating Clover’s COVID-19 vaccine candidate, SCB-2019, including follow-up efficacy at five months following primary vaccination and immune responses after a booster dose.
-
Clover to Participate at Upcoming Investor Conferences - Mar 03, 2022
3/3/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced its participation in three upcoming investor conferences.
-
Clover Selected for Inclusion on the Hang Seng Composite Index
2/24/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022.
-
Clover Provides Corporate Update and 2022 Priorities
2/14/2022
Clover announces universal COVID-19 vaccine booster development plan to support global use of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
-
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
2/1/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointment of Nicholas Jackson, Ph.D., as President of Global Research and Development.
-
Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet
1/21/2022
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that final efficacy data from SPECTRA, a global Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet.
-
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
-
Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA
1/5/2022
Clover Biopharmaceuticals, Ltd. today announced that the first participants have been dosed with Clover’s COVID-19 vaccine candidate, SCB-2019,
-
Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai
1/5/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced it has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base, dubbed "Zhangjiang Pharma Valley", located in Zhangjiang Hi-Tech Park in Pudong, Shanghai.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Ascentage Pharma and Clover Biopharmaceuticals Announce Clinical Collaboration to Evaluate IAP Antagonist, APG-1387, plus the Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, for the Treatment of Peritoneal Carcinomatosis
12/9/2021
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has entered into a clinical collaboration with Clover Biopharmaceuticals, Ltd.
-
Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis
12/9/2021
Clover Biopharmaceuticals, Ltd. and Ascentage Pharma announced that they have entered into a clinical collaboration to evaluate Clover’s SCB-313, a recombinant human TRAIL-Trimer fusion protein and Ascentage Pharma’s APG-1387, a second mitochondria-derived activator of caspase -mimetic/inhibitor of apoptosis proteins antagonist, in a Phase 1b/2 clinical trial for advanced peritoneal carcinomatosis.